Authorization from Health Canada for Medical Device Investigational Testing
August 12, 2024, OPTITHERA obtained and Investigational testing authorization for medical devices from Health Canada, to sell its test for investigational testing to the investigators of the clinical study entitled: New Genomic predictor for complication risk in type 2 diabetes (GENOCORDIA). The objective of the study is to provide Real World Evidence (RWE) on the […]
A World-First in Genomics, a Saliva Test to Predict Complications Associated with Type 2 Diabetes, Powered by an Important Public-Private Partnership
A new agreement has been signed between OPTITHERA, ELNA Medical Group, and Génome Québec as part of Genome Canada’s Genomic Applications Partnership Program (GAPP). This partnership will ensure the final steps required to bring to market the first-ever genomic test predicting the risk of diabetic complications.
Genome Canada funding supports impact-focused genomics research and development projects.
The Honourable François-Philippe Champagne, Minister of Innovation, Science and Industry, announced more than $41 million in government and private funding in support to eight new genomics research projects funded through Genome Canada’s Genomic Applications Partnership Program (GAPP).
Génome Québec allocates $ 1,9 M to the OPTITHERA project.
Génome Québec is particularly proud of the performance of Québec teams in a pan-Canadian competition. Over $23 million will be invested in genomics in Québec, including $5.4 million through Génome Québec. In fact, 49% of the available Canadian envelope was allocated to Québec projects. These investments will accelerate the commercialization and increase its real-world applications.
OPTITHERA’s scientists contribute to shared data resources on prioritized genes of kidney function decline to help drug development pipelines.
Need more information about this research?
OPTITHERA’s scientists contributed to the identification of diabetes-specific and non-diabetes specific genes of altered kidney function.
Need more information about this research?
Polygenic risk scores predict diabetes complications and their response to intensive blood pressure and glucose control
Need more information about this research?
OPTITHERA confirms that the introduction of its multiPRS test is cost effective in the care of renal complications of patients with diabetes
Need more information about this research?
Innove-Action Conference @CHUM
Session on advances in personalized #medicine to improve prevention and treatment of chronic diseases. #innoveaction #chum #InnoveActionCHUM
Polygenic risk: What’s the score?
Researchers are improving risk prediction for common chronic diseases using genetic data. These ‘polygenic risk scores’ can help personalize preventive measures and could soon become part of routine healthcare practice, once some limitations are overcome. Need more information about this research?
